Fortress Biotech, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables
Fortress Biotech, Inc. (FBIO) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables of $4.89 million as of 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill, Less Noncontrolling Interest › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables · last filed 2018-03-16
- 2017-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $4.89M.
- 2017-03-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $4.89M.
- 2016-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $4.89M.
- 2016-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $4.89M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables |
|---|---|
| 2017-12-31 | $4.89M 10-K · filed 2018-03-16 |
| 2017-03-31 | $4.89M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $4.89M 10-K · filed 2017-03-16 |
| 2016-09-30 | $4.89M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |